Waypoint Capital Advisors’s AbbVie ABBV Stock Holding History

Waypoint Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$872K	Buy	4,417 +160	+4%	+$29.9K	0.19%	75
2024 Q2	$730K	Buy	4,257 +157	+4%	+$26K	0.18%	77
2024 Q1	$747K	Buy	4,100 +66	+2%	+$11.4K	0.2%	74
2023 Q4	$625K	Sell	4,034 -109	-3%	-$15.9K	0.18%	76
2023 Q3	$618K	Buy	4,143 +1,778	+75%	+$261K	0.21%	71
2023 Q2	$319K	Buy	2,365 +63	+3%	+$9.24K	0.1%	113
2023 Q1	$367K	Sell	2,302 -1	-0%	-$153	0.12%	100
2022 Q4	$372K	Buy	2,303 +11	+0.5%	+$1.69K	0.13%	99
2022 Q3	$307K	Buy	2,292 +1	+0%	+$143	0.13%	92
2022 Q2	$351K	Sell	2,291 -40	-2%	-$6.11K	0.16%	84
2022 Q1	$376K	Sell	2,331 -63	-3%	-$9.15K	0.22%	80
2021 Q4	$324K	Buy	+2,394	New	+$283K	0.22%	70

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Waypoint Capital Advisors's ABBV Position: Q3 2024 in Review

Waypoint Capital Advisors increased its AbbVie (ABBV) stake by 3.8% in Q3 2024, buying an estimated $29.9K and bringing the position to 4,417 shares worth $872K. The position accounts for 0.19% of the portfolio, ranked #75.

Waypoint Capital Advisors first reported a position in ABBV in Q4 2021 and has held it in 12 quarters since. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

Waypoint Capital Advisors held 4,417 shares of AbbVie worth $872K as of Q3 2024.
Waypoint Capital Advisors bought 160 AbbVie shares in Q3 2024, an estimated $29.9K.
AbbVie made up 0.19% of Waypoint Capital Advisors's portfolio in Q3 2024, its #75 holding.
Waypoint Capital Advisors first reported a position in AbbVie in Q4 2021 and has held it in 12 quarters since.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Waypoint Capital Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.